|
|
|
| Recent research on mechanisms of resistance to macrolides in Mycoplasma pneumonia |
| NI Shan-shan, SUN Hong-mei |
| Capital Institute of Pediatrics, Beijing 100020, China |
|
|
|
|
Abstract Mycoplasma pneumoniae is the main pathogen of community-acquired pneumonia. Macrolide antibiotics are the first choice for the treatment of M. pneumoniae infection in children. In recent years, macrolide-resistant M. pneumoniae proportion has declined in China, but it is still at a high level. Drug-resistant M. pneumoniae infection causes prolonged fever and hospitalization time, and has a higher incidence of complications and change rate of antibiotic regimen. Therefore, further research is needed on the mechanism of drug resistance of M. pneumoniae. The mechanism of M. pneumoniae resistance to macrolide antibiotics is mainly related to the target mutation of antibiotic action, the modification of antibiotic targets, the active efflux of drugs, and the inactivation of enzymes.
|
|
Received: 04 December 2017
|
|
|
| Fund:Supported by the grants from the National Nature Science Foundation of China (No.81672062) |
|
Corresponding Authors:
Sun Hong-mei, Email:s.hongmei@263.net
|
|
|
|
[1] Chalker V, Stocki T, Litt D, et al.Increased detection of Mycoplasma pneumoniae infection in children in England and Wales, October 2011 to January 2012[J]. Euro surveill, 2012,17(6):5-9.
[2] Eibach D, Casalegno J S, Escuret V, et al.Increased detection of Mycoplasma pneumoniae infection in children, Lyon, France, 2010 to 2011.[J]. Euro surveill, 2012,17(8):2-4.
[3] Zhao HQ, Li SL, Cao L, et al.Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012[J]. Chin Med J, 2014,127(7):1244-1248. DOI:10.3760/cma.j.issn.0366-6999.20131654
[4] Rca DG, Meyer Sauteur PM, Wwj U, et al.Things that could be Mycoplasma pneumoniae[J]. J Infect, 2017,74:S95-S100. DOI: 10.1016/S0163-4453(17)30198-6
[5] Spuesens EB, Meyer Sauteur PM, Vink C, et al.Mycoplasma pneumoniae infections-does treatment help[J]. J Infect, 2014,69:S42-S46. DOI: 10.1016/j.jinf.2014.07.017
[6] Cherazard R, Epstein M, Doan TL, et al.Antimicrobial resistant Strptococcus pneumoniae: prevalence, mechanisms, and clinical implications[J]. Am J Ther,2017,24:361-369. DOI: 10.1097/MJT.0000000000000551
[7] 林江涛,张永明,王长征,等.大环内酯类药物的抗菌外作用与临床应用专家共识[J]. 中华内科杂志, 2017,56(7):546-557.DOI:10.3760/cma.j.issn.0578-1426.2017.07.015
[8] Lovmar M, Tenson TM.Kinetics of macrolide action: the josamycin and erythromycin cases[J]. J Biol Chem, 2004,279(51):53506-53515. DOI: 10.1074/jbc.M401625200
[9] Leclercq R, Courvalin P.Resistance to macrolides and related antibiotics in Streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 2002,46:2727-2734. DOI: 10.1128/AAC.46.9.2727-2734.2002
[10] Liu Y, Ye X, Zhang H, et al.Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China[J]. Antimicrob Agents Chemother, 2009,53(5):2160-2162.DOI: 10.1128/AAC.01684-08
[11] 赵茂茂,宋波,蒲增惠,等.肺炎支原体对抗菌药物敏感性及对大环内酯类的耐药机制研究[J]. 中华医院感染学杂志, 2014,24(20):5027-5029.DOI: 10.11816/cn.ni.2014-133927
[12] 郑宝英,闫超,薛冠华,等.耐药肺炎支原体肺炎患儿的临床特点及流行基因型特征分析[J]. 中华实用儿科临床杂志, 2017,32(10):735-739.DOI: 10.3760/cma.j.issn.2095-428X.2017.10.005
[13] Morozumi M, Iwata S, Hasegawa K, et al.Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia[J]. Antimicrob Agents Chemother, 2008,52(1):348-350. DOI: 10.1128/AAC.00779-07
[14] Matsubara K, Morozumi M, Okada T, et al.A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients[J]. J Infect Chemother, 2009,15(6):380-383. DOI: 10.1007/s10156-009-0715-7
[15] Tanaka T, Oishi T, Miyata I, et al.Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015.[J]. Emerg Infect Dis, 2017,23(10):1703-1706. DOI: 10.3201/eid2310.170106
[16] Kawai Y, Miyashita N, Kubo M, et al.Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients[J]. Antimicrob Agents Chemother, 2013,57(8):4046-4049. DOI: 10.1128/AAC.00663-13
[17] Wolff BJ, Thacker WL, Schwartz SB, et al.Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and High-resolution melt analysis[J]. Antimicrob Agents Chemother, 2008,52(10):3542-3549. DOI: 10.1128/AAC.00582-08
[18] Piazzon ML, Wang H, Everhart K, et al.Mycoplasma pneumoniae macrolide resistance in children in central ohio detected by sequencing[J]. Open Forum Infect Dis, 2017,4(suppl_1):S500. DOI: 10.1093/ofid/ofx163.1296
[19] Wu PS, Chang LY, Lin HC, et al.Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan[J]. Pediatr Pulmonol, 2013,48(9):904-911. DOI: 10.1002/ppul.22706
[20] Schlünzen F, Zarivach R, Harms J, et al.Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria.[J]. Nature, 2001,413(6858):814-821. DOI: 10.1038/35101544
[21] Spuesens EBM.Mycoplasma pneumoniae: Bacterial genetic variation and colonization of the respiratory tract of children[D]. The Netherlands:Erasmus University Rotterdam, 2016:1-218.
[22] Lucier TS, Heitzman K, Liu SK, et al.Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae[J]. Antimicrob Agents Chemother, 1995,39(12):2770-2773. DOI: 10.1128/AAC.39.12.2770
[23] Pereyre S, Guyot C, Renaudin H, et al.In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae[J]. Antimicrob Agents Chemother,2004,48(2):460-465. DOI: 10.1128/AAC.48.2.460-465.2004
[24] Okazaki N, Narita M, Yamada S, et al.Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro[J]. Microbiol Immunol, 2001, 45(8): 617-620. DOI: 10.1111/j.1348-0421.2001.tb01293.x
[25] Zhao HQ, Li SL, Cao L, et al.Surveillance of Mycoplasma pneumoniae infection among children in Beijing from 2007 to 2012[J]. Chin Med J (Engl), 2014, 127(7): 1244-1248. DOI: 10.3760/cma.j.issn.0366-6999.20131654
[26] Sun HM, Xue GH, Yan C, et al.Changes in molecular characteristics of Mycoplasma pneumoniae in clinical specimens from children in Beijing between 2003 and 2015[J]. PLoS One, 2017, 12(1): e170253-e170262. DOI: 10.1371/journal.pone.0170253
[27] Ma Z, Zheng Y, Deng J, et al.Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen,China[J]. Pediatr Pulmonol, 2014,49:695-700. DOI: 10.1002/ppul.22851
[28] Kogoj R, Mrvic T, Praprotnik M, et al. Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014.[J]. Euro surveill, 2015,20(37):30018-30025. DOI: 10.2807/1560-7917.ES.2015.20.37.30018
[29] Loo LH, Soong HY, Maiwald M, et al.Assessment of genotypic macrolide resistance among Mycoplasma pneumoniae infections in children in Singapore[J]. Ann Acad Med Singapore, 2017,46(7):290-292.
[30] Cao B, Qu JX, Yin YD, et al.Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance[J]. Clin Respir J, 2017,11(4):419-429 DOI: 10.1111/crj.12379
[31] Suzuki Y, Seto J, Itagaki T, et al.Gene mutations associated with macrolide-resistance and p1 gene typing of Mycoplasma pneumoniae isolated in Yamagata, Japan, between 2004 and 2013[J]. Kansenshogaku Zasshi, 2015,89(1):16-22. DOI: 10.11150/kan-senshogakuzasshi.89.16
[32] Zaman SM, Lindahl L, Zengel J.Novel mutations in ribosomal proteins L4 and L22 that confer erythromycin resistance in Escherichia coli[J]. Mol Microbiol, 2007,66(4):1039-1050. DOI: 10.1111/j.1365-2958.2007.05975.x
[33] O’Connor M, Gregory ST, Dahlberg AE. Multiple defects in translation associated with altered ribosomal protein L4[J]. Nucleic Acids Res, 2004,32(19):5750-5756. DOI: 10.1093/nar/gkh913
[34] Gabashvili IS, Gregory ST, Valle M, et al.The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22.[J]. Mol Cell, 2001,8(1):181-188. DOI: 10.1016/S1097-2765(01)00293-3
[35] Matsuoka M, Narita M, Okazaki N, et al.Characterization and molecular analysis of macrolide resistant Mycoplasma pneumoniae clinical isolates obtained in Japan[J]. Antimicrob Agents Chemother, 2004,48(12):4624-4630. DOI: 10.1128/AAC.48.12.4624-4630.2004
[36] Liu X, Jiang Y, Chen X, et al.Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics[J]. Biomed Res Int, 2014,2014(5):320801-320807. DOI: 10.1155/2014/320801
[37] 唐愈菲,胡新年,欧广利,等.次抑菌浓度大环内酯类药物诱导肺炎支原体耐药机制研究[J]. 中国病原生物学杂志, 2016,11(1):25-29.DOI:10.13350/j.cjpb.160107
[38] Szczypa K, Sadowy E, Izdebski R, et al.Group A streptococci from invasive-disease episodes in Poland are remarkably divergent at the molecular level[J]. J Clin Microbiol, 2006,44(11):3975-3979. DOI: 10.1128/JCM.01163-06
[39] 郑定容,黄龙,周伟.肺炎支原体培养及药敏试验和耐药基因分析[J].中国卫生检验杂志,2013(5):1302-1304.
[40] 苑鑫. 肺炎支原体耐药机制的研究[D].北京:中国人民解放军总医院, 2012:1-97.
[41] 韩旭,辛德莉.肺炎支原体对大环内酯类抗生素的耐药机制[J].中华实用儿科临床杂志, 2006,21(16):1101-1103. DOI: 10.3969/j.issn.1003-515X.2006.16.031
[42] Li SL, Sun HM, Zhu BL, et al.Whole genome analysis reveals new insights into macrolide resistance in Mycoplasma pneumoniae[J]. Biomed Environ Sci, 2017,30(5):343-350. DOI: 10.3967/bes2017.045
[43] 王辉, 陈民钧. 肺炎链球菌对红霉素耐药机制的研究[J]. 中华检验医学杂志, 2002,25(3):137-140.DOI:10.3760/j:issn:1009-9158.2002.03.003
[44] Noguchi N, Katayama J, Sasatsu M.A transposon carrying the gene mphB for macrolide 2'-phosphotransferase II.[J]. FEMS Microbiol Lett, 2000,192(2):175-178. DOI: 10.1111/j.1574-6968.2000.tb09378.x
[45] Quirós LM, Carbajo RJ, Salas JA.Inversion of the anomeric configuration of the transferred sugar during inactivation of the macrolide antibiotic oleandomycin catalyzed by a macrolide glycosyltransferase[J]. FEBS Lett, 2000,476(3):186-189. DOI: 10.1016/S0014-5793(00)01721-X
[46] Kim YH, Cha CJ, Cerniglia CE.Purification and characterization of an erythromycin esterase from an erythromycin-resistant Pseudomonas sp[J]. FEMS Microbiol Lett, 2002,210(2):239-244. DOI: 10.1111/j.1574-6968.2002.tb11187.x |
|
|
|
2018, Vol. 34 
